Curis (CRIS) Reports Encouraging Emavusertib Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Curis (CRIS) Reports Encouraging Emavusertib Data
June 6, 2022 6:32 AM EDT
H.C. Wainwright analyst Edward P. White reiterated a Buy rating and $16.00 price target on Curis (NASDAQ: CRIS)
The analyst comments "This past weekend, Curis presented updated data for emavusertib (CA-4948) in combination with Imbruvica (ibrutinib) in patients with NonHodgkins Lymphoma (NHL) at ASCO. The open-label, dose escalation, dose expansion, Phase 1/2 TakeAim Lymphoma study is evaluating emavusertib as monotherapy and in combination with Imbruvica in patients with relapsed or refractory... More
June 6, 2022 6:26 AM EDT
Laidlaw analyst Yale Jen reiterated a Buy rating and $22.00 price target on Curis (NASDAQ: CRIS)
The analyst comments "The TakeAim Leukemia study data reported at the ASCO were similar to what was reported this January. In addition to the initial monotherapy results, for the TakeAim Lymphoma study, major new data were the initial emavusertib and ibrutinib combo study readouts. The key takeaways are that eight of nine evaluable patients experienced reduction in tumor burden with two CR, two PR, and five SD. Specifically, among the four who received... More
June 6, 2022 6:15 AM EDT
Curis (NASDAQ: CRIS) Climbs 28% Premarket
...
More
